Subcutaneous therapy improves inflammatory bowel disease treatment, clinical trial finds

Linear scale mean (SD) serum infliximab concentrations up to week 54 (PK population) in the CD (A) and UC (B) studies. Concentrations below the lower limit of quantification (BLQ) before first study drug administration (wk 0) were set to 0. Concentrations BLQ after study drug exposure were set equal to lower limit of quantification. For patients who underwent dose adjustment, only data collected before dose adjustment were included in the figure. Credit: Gastroenterology (2024). DOI: 10.1053/j.gastro.2024.05.006 Subcutaneous delivery of an anti-TNF inhibitor drug improved remission rates in patients with moderate-to-severe Crohn’s disease and ulcerative colitis, according to recent phase 3 Read More